LYELL IMMUNOPHARMA INC (LYEL) Stock Analyst Ratings
USA - NASDAQ:LYEL - US55083R2031 - Common Stock
16.93 USD
-0.48 (-2.76%)
ChartMill assigns a Buy % Consensus number of 48% to LYEL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 14.28. This target is -15.65% below the current price.
LYEL was analyzed by 8 analysts. The buy percentage consensus is at 48. So analysts seem to be rather neutral about LYEL.
In the previous month the buy percentage consensus was at a similar level.
LYEL was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-26 | LUCID CAPITAL MARKETS | Initiate | Buy |
| 2025-06-24 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-04-16 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-03-13 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-10-30 | B of A Securities | Downgrade | Buy -> Underperform |
| 2024-10-28 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-08-19 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-06-27 | B of A Securities | Maintains | Buy -> Buy |
| 2024-06-27 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-05-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-28 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2023-05-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-02 | HC Wainwright & Co. | Maintains | Buy |
| 2023-01-24 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-11-14 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2022-11-11 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-10-17 | HC Wainwright & Co. | Initiate | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2022-01-06 | Morgan Stanley | Maintains | Overweight |
| 2021-07-12 | JP Morgan | Initiate | Overweight |
| 2021-07-12 | Goldman Sachs | Initiate | Buy |
| 2021-07-12 | B of A Securities | Initiate | Buy |
| 2021-07-12 | Morgan Stanley | Initiate | Overweight |
LYELL IMMUNOPHARMA INC / LYEL FAQ
What is the average price target for LYELL IMMUNOPHARMA INC (LYEL) stock?
8 analysts have analysed LYEL and the average price target is 14.28 USD. This implies a price decrease of -15.65% is expected in the next year compared to the current price of 16.93.
How do analysts rate LYELL IMMUNOPHARMA INC (LYEL)?
The consensus rating for LYELL IMMUNOPHARMA INC (LYEL) is 47.5 / 100 . This indicates that analysts generally have a neutral outlook on the stock.